Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment

General Hospital Psychiatry

Volumn 32, Issue 4, 2010, Pages 426-432

  Holtzheimer, Paul E ^a   Veitengruber, Jason ^b   Wang, Chia C ^b   Krows, Meighan ^b   Thiede, Hanne ^c   Wald, Anna ^b,d   Roy Byrne, Peter ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^d USA   (United States)

Author keywords

Acute hepatitis C; Depression; Injection drug use; Interferon alpha; Screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DIAMORPHINE; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PEGINTERFERON; VENLAFAXINE; ALPHA INTERFERON; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG OVERDOSE; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HUMAN; MALE; NEGATIVE PREDICTIVE VALUE; POSITIVE PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SEMI STRUCTURED INTERVIEW; SENSITIVITY AND SPECIFICITY; SUICIDAL IDEATION; COMPLICATION; DEPRESSIVE DISORDER; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REPRODUCIBILITY; SUBSTANCE ABUSE;

ADULT; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE, INTRAVENOUS; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77954622397     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.02.001     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention: 2006 Disease Profile 2008, 17-26.
2. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
3. Asnis G.M., De La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006, 40:322-335.
4. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457.
5. Kamal S.M., Moustafa K.N., Chen J., Fehr J., Abdel Moneim A., Khalifa K.E., et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006, 43:923-931.
6. Wiegand J., Buggisch P., Boecher W., Zeuzem S., Gelbmann C.M., Berg T., et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43:250-256.
7. Hagan H., Latka M.H., Campbell J.V., Golub E.T., Garfein R.S., Thomas D.A., et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006, 42:669-672.
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
9. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
10. Wild T.C., el-Guebaly N., Fischer B., Brissette S., Brochu S., Bruneau J., et al. Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study. Can J Psychiatry 2005, 50:512-518.
11. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007.
12. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
13. Munoz M., Vazquez C., Koegel P., Sanz J., Burnam M.A. Differential patterns of mental disorders among the homeless in Madrid (Spain) and Los Angeles (USA). Soc Psychiatry Psychiatr Epidemiol 1998, 33:514-520.
14. Gunderson J.G., Morey L.C., Stout R.L., Skodol A.E., Shea M.T., McGlashan T.H., et al. Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry 2004, 65:1049-1056.
15. Beck A.T., Ward C.H., Mendelsohn M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
16. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000, 157:867-876.
17. Golden J., Conroy R.M., O'Dwyer A.M. Reliability and validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory (Full and FastScreen scales) in detecting depression in persons with hepatitis C. J Affect Disord 2007, 100:265-269.
18. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
19. Garfein R.S., Swartzendruber A., Ouellet L.J., Kapadia F., Hudson S.M., Thiede H., et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend 2007, 91(Suppl 1):S4-17.
20. Garfein R.S., Golub E.T., Greenberg A.E., Hagan H., Hanson D.L., Hudson S.M., et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS 2007, 21:1923-1932.
21. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33. quiz 34-57.